YSB Inc. (HK:9885)
:9885
Want to see HK:9885 full AI Analyst Report?
Top Page
YSB Inc.
(9885)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$4.00
▼(-22.48% Downside)
Action:Reiterated
Date:05/19/26
The score is primarily supported by improving financial performance, led by consistently positive and growing free cash flow and a return to profitability in 2025. However, the overall rating is held back by sharply weaker technicals (price below key moving averages and bearish momentum) and heightened balance-sheet risk from increased leverage, despite a reasonable valuation (low P/E and moderate dividend yield).
Positive Factors
Cash Generation
Consistently positive and growing free cash flow (FCF up ~27% in 2025) provides durable internal funding for operations, R&D, and shareholder returns without immediate external financing. Strong FCF alignment with reported profits enhances earnings credibility and cushions the business through cyclical pressure.
Negative Factors
Low Margins
Margins are very thin for a software company (gross ~11%, net <1% in 2025), leaving profits highly sensitive to small cost increases or pricing pressure. Persistently low margins constrain reinvestment, limit operating leverage benefits, and raise the bar for sustainable, high-quality earnings growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Generation
Consistently positive and growing free cash flow (FCF up ~27% in 2025) provides durable internal funding for operations, R&D, and shareholder returns without immediate external financing. Strong FCF alignment with reported profits enhances earnings credibility and cushions the business through cyclical pressure.
Read all positive factors
YSB Inc. (9885) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.64B
Dividend Yield1.38%
Average Volume (3M)9.20M
Price to Earnings (P/E)21.9
Beta (1Y)0.82
Revenue Growth17.22%
EPS Growth385.91%
CountryHK
Employees6,763
SectorHealthcare
Sector Strength45
IndustrySoftware - Application
Share Statistics
EPS (TTM)0.22
Shares Outstanding688,070,900
10 Day Avg. Volume7,414,414
30 Day Avg. Volume9,200,413
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.37
Price to Sales (P/S)0.16
P/FCF Ratio5.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.38
Revenue Forecast (FY)HK$23.46B
YSB Inc. Business Overview & Revenue Model
Company Description
YSB Inc. develops digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China. It develops ClouDiagnos for diagnostic testing service; wePharmacy, a 24-hour access s...
YSB Inc. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
49
Neutral
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.97B | 17.90B | 16.97B | 14.27B | 10.09B |
| Gross Profit | 2.31B | 1.81B | 1.74B | 1.43B | 913.83M |
| EBITDA | 133.97M | -42.13M | -3.07B | -1.35B | -392.32M |
| Net Income | 152.97M | 30.01M | -3.21B | -1.50B | -501.62M |
Balance Sheet | |||||
| Total Assets | 7.57B | 6.50B | 5.21B | 4.11B | 3.44B |
| Cash, Cash Equivalents and Short-Term Investments | 3.38B | 1.99B | 1.83B | 1.87B | 1.14B |
| Total Debt | 2.77B | 233.51M | 209.66M | 180.55M | 181.73M |
| Total Liabilities | 5.18B | 4.23B | 3.33B | 8.48B | 6.35B |
| Stockholders Equity | 2.44B | 2.32B | 1.92B | -4.35B | -2.90B |
Cash Flow | |||||
| Free Cash Flow | 619.46M | 632.46M | 433.65M | 54.49M | -608.06M |
| Operating Cash Flow | 637.70M | 655.86M | 451.20M | 98.20M | -487.09M |
| Investing Cash Flow | -896.27M | -253.58M | -792.95M | 41.07M | -352.80M |
| Financing Cash Flow | -70.97M | -109.81M | 255.34M | 261.93M | 1.12B |
YSB Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$3.64B | 24.36 | -8.12% | ― | 3.16% | ― | |
62 Neutral | HK$1.76B | 28.22 | 8.53% | ― | 14.29% | 142.01% | |
58 Neutral | HK$2.64B | 21.92 | 6.36% | 1.38% | 17.22% | 385.91% | |
56 Neutral | HK$28.13B | 452.18 | 1.71% | ― | 12.11% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$4.26B | -421.50 | -1.00% | ― | 10.59% | 98.05% | |
42 Neutral | HK$5.70B | -27.23 | -66.11% | ― | 18.94% | 89.36% |
* Healthcare Sector Average
HK:9885
YSB Inc.
3.90
-4.36
-52.78%
HK:8083
China Youzan
0.11
0.02
20.65%
HK:0268
Kingdee International Software Group Co
7.94
-4.88
-38.07%
HK:2013
Weimob
1.39
-0.48
-25.67%
HK:1588
Chanjet Information Technology Co., Ltd. Class H
5.40
-0.81
-13.07%
HK:6657
Baiwang Co., Ltd. Class H
11.80
-24.00
-67.04%
YSB Inc. Corporate Events
YSB Inc. Sets 2026 AGM to Approve Dividend, Board Changes and Share Mandates
Apr 23, 2026
YSB Inc. has called its annual general meeting for 21 May 2026 in Guangzhou, where shareholders will review the audited financial statements for the year ended 31 December 2025 and vote on a proposed final dividend of RMB0.110 per share. Investors...
YSB Inc. Awards Over 32 Million Share Options to Top Executives Under 2023 Incentive Plan
Mar 24, 2026
YSB Inc. has granted a total of 32,551,518 share options to two senior executives under its 2023 Share Incentive Plan, signaling a substantial equity-based reward for top management. The options, tied to existing shares acquired on the market by a...
YSB Inc. Hits 2025 Earn-Out Targets on Strategic Acquisition and Issues Contingent Shares
Mar 23, 2026
YSB Inc. reported strong progress on its previously announced acquisition of a target company, noting that integration has advanced effectively and resource reuse and channel synergies are yielding concrete results in line with expectations. The c...
YSB Inc. Declares Final 2025 Cash Dividend for Hong Kong Shareholders
Mar 23, 2026
YSB Inc. has proposed a final ordinary cash dividend of RMB 0.11 per share for the financial year ended 31 December 2025, equivalent to HKD 0.125 per share based on an exchange rate of RMB 1 to HKD 1.137. The payout, subject to shareholder approva...
YSB Inc. posts strong 2025 earnings as digital pharma platform strategy pays off
Mar 23, 2026
YSB Inc. reported robust results for 2025, with revenue rising 17.1% year on year to RMB20.97 billion, driven mainly by an 18.2% increase in its self-operation business while online marketplace revenue dipped slightly. Gross profit climbed 27.2% t...
YSB Inc. Schedules Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
Mar 11, 2026
YSB Inc. has announced that its board of directors will convene on 23 March 2026 to review and approve the group’s audited annual results for the financial year ended 31 December 2025. The meeting will also consider the publication of these ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.